Format
Sort by
Items per page

Send to

Choose Destination

Best matches for Lünemann JD[au]:

Efficacy of Intravenous Immunoglobulin in Neurological Diseases. Lünemann JD et al. Neurotherapeutics. (2016)

Intravenous immunoglobulin in neurology--mode of action and clinical efficacy. Lünemann JD et al. Nat Rev Neurol. (2015)

Immune reconstitution therapies: concepts for durable remission in multiple sclerosis. Lünemann JD et al. Nat Rev Neurol. (2020)

Search results

Items: 1 to 50 of 84

1.

Xenogeneic Neu5Gc and self-glycan Neu5Ac epitopes are potential immune targets in MS.

Boligan KF, Oechtering J, Keller CW, Peschke B, Rieben R, Bovin N, Kappos L, Cummings RD, Kuhle J, von Gunten S, Lünemann JD.

Neurol Neuroimmunol Neuroinflamm. 2020 Feb 3;7(2). pii: e676. doi: 10.1212/NXI.0000000000000676. Print 2020 Mar.

2.

Author Correction: Immune reconstitution therapies: concepts for durable remission in multiple sclerosis.

Lünemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H.

Nat Rev Neurol. 2020 Feb;16(2):125. doi: 10.1038/s41582-020-0310-1.

PMID:
31937911
3.

Impact of FcγR variants on the response to alemtuzumab in multiple sclerosis.

Keller CW, Ruck T, McHugh D, Pfeuffer S, Gross CC, Korsukewitz C, Melzer N, Klotz L, Meuth SG, Münz C, Nimmerjahn F, Wiendl H, Lünemann JD.

Ann Clin Transl Neurol. 2019 Dec;6(12):2586-2594. doi: 10.1002/acn3.50935. Epub 2019 Nov 4.

4.

Immune reconstitution therapies: concepts for durable remission in multiple sclerosis.

Lünemann JD, Ruck T, Muraro PA, Bar-Or A, Wiendl H.

Nat Rev Neurol. 2020 Jan;16(1):56-62. doi: 10.1038/s41582-019-0268-z. Epub 2019 Oct 24. Review. Erratum in: Nat Rev Neurol. 2020 Feb;16(2):125.

PMID:
31649335
5.

Characterization of the human myelin oligodendrocyte glycoprotein antibody response in demyelination.

Tea F, Lopez JA, Ramanathan S, Merheb V, Lee FXZ, Zou A, Pilli D, Patrick E, van der Walt A, Monif M, Tantsis EM, Yiu EM, Vucic S, Henderson APD, Fok A, Fraser CL, Lechner-Scott J, Reddel SW, Broadley S, Barnett MH, Brown DA, Lunemann JD, Dale RC, Brilot F; Australasian and New Zealand MOG Study Group.

Acta Neuropathol Commun. 2019 Sep 3;7(1):145. doi: 10.1186/s40478-019-0786-3.

6.

IVIG efficacy in CIDP patients is not associated with terminal complement inhibition.

Keller CW, Quast I, Dalakas MC, Lünemann JD.

J Neuroimmunol. 2019 May 15;330:23-27. doi: 10.1016/j.jneuroim.2019.02.001. Epub 2019 Feb 10.

PMID:
30772754
7.

Endocytosis regulation by autophagy proteins in MHC restricted antigen presentation.

Keller CW, Loi M, Ligeon LA, Gannagé M, Lünemann JD, Münz C.

Curr Opin Immunol. 2018 Jun;52:68-73. doi: 10.1016/j.coi.2018.04.014. Epub 2018 Apr 30. Review.

PMID:
29719275
8.

Noncanonical autophagy in dendritic cells triggers CNS autoimmunity.

Keller CW, Lünemann JD.

Autophagy. 2018;14(3):560-561. doi: 10.1080/15548627.2018.1427397. Epub 2018 Feb 17.

9.

Interleukins 12 and 15 induce cytotoxicity and early NK-cell differentiation in type 3 innate lymphoid cells.

Raykova A, Carrega P, Lehmann FM, Ivanek R, Landtwing V, Quast I, Lünemann JD, Finke D, Ferlazzo G, Chijioke O, Münz C.

Blood Adv. 2017 Dec 14;1(27):2679-2691. doi: 10.1182/bloodadvances.2017008839. eCollection 2017 Dec 26.

10.

ATG-dependent phagocytosis in dendritic cells drives myelin-specific CD4+ T cell pathogenicity during CNS inflammation.

Keller CW, Sina C, Kotur MB, Ramelli G, Mundt S, Quast I, Ligeon LA, Weber P, Becher B, Münz C, Lünemann JD.

Proc Natl Acad Sci U S A. 2017 Dec 26;114(52):E11228-E11237. doi: 10.1073/pnas.1713664114. Epub 2017 Dec 12.

11.

Fc-Galactosylation of Human Immunoglobulin Gamma Isotypes Improves C1q Binding and Enhances Complement-Dependent Cytotoxicity.

Peschke B, Keller CW, Weber P, Quast I, Lünemann JD.

Front Immunol. 2017 Jun 6;8:646. doi: 10.3389/fimmu.2017.00646. eCollection 2017.

12.

Reciprocal Crosstalk between Dendritic Cells and Natural Killer T Cells: Mechanisms and Therapeutic Potential.

Keller CW, Freigang S, Lünemann JD.

Front Immunol. 2017 May 24;8:570. doi: 10.3389/fimmu.2017.00570. eCollection 2017. Review.

13.

Immune and myodegenerative pathomechanisms in inclusion body myositis.

Keller CW, Schmidt J, Lünemann JD.

Ann Clin Transl Neurol. 2017 May 16;4(6):422-445. doi: 10.1002/acn3.419. eCollection 2017 Jun. Review.

14.

IVIG regulates the survival of human but not mouse neutrophils.

Schneider C, Wicki S, Graeter S, Timcheva TM, Keller CW, Quast I, Leontyev D, Djoumerska-Alexieva IK, Käsermann F, Jakob SM, Dimitrova PA, Branch DR, Cummings RD, Lünemann JD, Kaufmann T, Simon HU, von Gunten S.

Sci Rep. 2017 May 2;7(1):1296. doi: 10.1038/s41598-017-01404-0.

15.

The autophagy machinery restrains iNKT cell activation through CD1D1 internalization.

Keller CW, Loi M, Ewert S, Quast I, Theiler R, Gannagé M, Münz C, De Libero G, Freigang S, Lünemann JD.

Autophagy. 2017 Jun 3;13(6):1025-1036. doi: 10.1080/15548627.2017.1297907. Epub 2017 Mar 15.

16.

Autophagy and Autophagy-Related Proteins in CNS Autoimmunity.

Keller CW, Lünemann JD.

Front Immunol. 2017 Feb 27;8:165. doi: 10.3389/fimmu.2017.00165. eCollection 2017. Review.

17.

Terminal complement activation is increased and associated with disease severity in CIDP.

Quast I, Keller CW, Hiepe F, Tackenberg B, Lünemann JD.

Ann Clin Transl Neurol. 2016 Jul 25;3(9):730-5. doi: 10.1002/acn3.331. eCollection 2016 Sep.

18.

Regulation of antibody effector functions through IgG Fc N-glycosylation.

Quast I, Peschke B, Lünemann JD.

Cell Mol Life Sci. 2017 Mar;74(5):837-847. doi: 10.1007/s00018-016-2366-z. Epub 2016 Sep 17. Review.

PMID:
27639381
19.

Infectious Mononucleosis Triggers Generation of IgG Auto-Antibodies against Native Myelin Oligodendrocyte Glycoprotein.

Kakalacheva K, Regenass S, Wiesmayr S, Azzi T, Berger C, Dale RC, Brilot F, Münz C, Rostasy K, Nadal D, Lünemann JD.

Viruses. 2016 Feb 12;8(2). pii: E51. doi: 10.3390/v8020051.

20.

Protection from experimental autoimmune encephalomyelitis by polyclonal IgG requires adjuvant-induced inflammation.

Quast I, Keller CW, Weber P, Schneider C, von Gunten S, Lünemann JD.

J Neuroinflammation. 2016 Feb 18;13:42. doi: 10.1186/s12974-016-0506-x.

21.

Rituximab induces clonal expansion of IgG memory B-cells in patients with inflammatory central nervous system demyelination.

Maurer MA, Tuller F, Gredler V, Berger T, Lutterotti A, Lünemann JD, Reindl M.

J Neuroimmunol. 2016 Jan 15;290:49-53. doi: 10.1016/j.jneuroim.2015.11.006. Epub 2015 Nov 19.

22.

Sialylation of IgG Fc domain impairs complement-dependent cytotoxicity.

Quast I, Keller CW, Maurer MA, Giddens JP, Tackenberg B, Wang LX, Münz C, Nimmerjahn F, Dalakas MC, Lünemann JD.

J Clin Invest. 2015 Nov 2;125(11):4160-70. doi: 10.1172/JCI82695. Epub 2015 Oct 5.

23.

Efficacy of Intravenous Immunoglobulin in Neurological Diseases.

Lünemann JD, Quast I, Dalakas MC.

Neurotherapeutics. 2016 Jan;13(1):34-46. doi: 10.1007/s13311-015-0391-5. Review.

24.

Deregulated Fcγ receptor expression in patients with CIDP.

Quast I, Cueni F, Nimmerjahn F, Tackenberg B, Lünemann JD.

Neurol Neuroimmunol Neuroinflamm. 2015 Aug 20;2(5):e148. doi: 10.1212/NXI.0000000000000148. eCollection 2015 Oct.

25.

Intravenous immunoglobulin in neurology--mode of action and clinical efficacy.

Lünemann JD, Nimmerjahn F, Dalakas MC.

Nat Rev Neurol. 2015 Feb;11(2):80-9. doi: 10.1038/nrneurol.2014.253. Epub 2015 Jan 6. Review.

PMID:
25561275
26.

Fc glycan-modulated immunoglobulin G effector functions.

Quast I, Lünemann JD.

J Clin Immunol. 2014 Jul;34 Suppl 1:S51-5. doi: 10.1007/s10875-014-0018-3. Epub 2014 Apr 24. Review.

PMID:
24760108
27.

TNF-α upregulates macroautophagic processing of APP/β-amyloid in a human rhabdomyosarcoma cell line.

Keller CW, Schmitz M, Münz C, Lünemann JD, Schmidt J.

J Neurol Sci. 2013 Feb 15;325(1-2):103-7. doi: 10.1016/j.jns.2012.12.011. Epub 2013 Jan 5.

PMID:
23294492
28.

The initiation and prevention of multiple sclerosis.

Ascherio A, Munger KL, Lünemann JD.

Nat Rev Neurol. 2012 Nov 5;8(11):602-12. doi: 10.1038/nrneurol.2012.198. Epub 2012 Oct 9. Review.

29.

Persistence of Epstein-Barr virus in self-reactive memory B cells.

Tracy SI, Kakalacheva K, Lünemann JD, Luzuriaga K, Middeldorp J, Thorley-Lawson DA.

J Virol. 2012 Nov;86(22):12330-40. doi: 10.1128/JVI.01699-12. Epub 2012 Sep 5.

30.

Rituximab induces sustained reduction of pathogenic B cells in patients with peripheral nervous system autoimmunity.

Maurer MA, Rakocevic G, Leung CS, Quast I, Lukačišin M, Goebels N, Münz C, Wardemann H, Dalakas M, Lünemann JD.

J Clin Invest. 2012 Apr;122(4):1393-402. doi: 10.1172/JCI58743. Epub 2012 Mar 19.

31.

Killer immunoglobulin-like receptor locus polymorphisms in multiple sclerosis.

Jelcić I, Hsu KC, Kakalacheva K, Breiden P, Dupont B, Uhrberg M, Martin R, Münz C, Lünemann JD.

Mult Scler. 2012 Jul;18(7):951-8. doi: 10.1177/1352458511431726. Epub 2011 Dec 20.

PMID:
22185807
32.

Epstein-Barr virus in multiple sclerosis: a continuing conundrum.

Lünemann JD.

Neurology. 2012 Jan 3;78(1):11-2. doi: 10.1212/WNL.0b013e318241f2b3. Epub 2011 Dec 7. No abstract available.

PMID:
22156986
33.

EBV-specific immune responses in patients with multiple sclerosis responding to IFNβ therapy.

Comabella M, Kakalacheva K, Río J, Münz C, Montalban X, Lünemann JD.

Mult Scler. 2012 May;18(5):605-9. doi: 10.1177/1352458511426816. Epub 2011 Oct 21.

PMID:
22020417
34.

Intrathymic Epstein-Barr virus infection is not a prominent feature of myasthenia gravis.

Kakalacheva K, Maurer MA, Tackenberg B, Münz C, Willcox N, Lünemann JD.

Ann Neurol. 2011 Sep;70(3):508-14. doi: 10.1002/ana.22488.

PMID:
21905082
35.

Expression and function of the inhibitory Fcγ-receptor in CIDP.

Nimmerjahn F, Lünemann JD.

J Peripher Nerv Syst. 2011 Jun;16 Suppl 1:41-4. doi: 10.1111/j.1529-8027.2011.00305.x.

PMID:
21696497
36.

Environmental triggers of multiple sclerosis.

Kakalacheva K, Lünemann JD.

FEBS Lett. 2011 Dec 1;585(23):3724-9. doi: 10.1016/j.febslet.2011.04.006. Epub 2011 Apr 7. Review.

37.

Impaired IFN-γ production and proliferation of NK cells in multiple sclerosis.

Lünemann A, Tackenberg B, DeAngelis T, da Silva RB, Messmer B, Vanoaica LD, Miller A, Apatoff B, Lublin FD, Lünemann JD, Münz C.

Int Immunol. 2011 Feb;23(2):139-48. doi: 10.1093/intimm/dxq463. Epub 2011 Jan 6.

38.

TNF-alpha induces macroautophagy and regulates MHC class II expression in human skeletal muscle cells.

Keller CW, Fokken C, Turville SG, Lünemann A, Schmidt J, Münz C, Lünemann JD.

J Biol Chem. 2011 Feb 4;286(5):3970-80. doi: 10.1074/jbc.M110.159392. Epub 2010 Oct 27.

39.

Targeting dendritic cells to treat multiple sclerosis.

Comabella M, Montalban X, Münz C, Lünemann JD.

Nat Rev Neurol. 2010 Sep;6(9):499-507. doi: 10.1038/nrneurol.2010.112. Epub 2010 Aug 17. Review.

PMID:
20717105
40.

Viral triggers of multiple sclerosis.

Kakalacheva K, Münz C, Lünemann JD.

Biochim Biophys Acta. 2011 Feb;1812(2):132-40. doi: 10.1016/j.bbadis.2010.06.012. Epub 2010 Jun 25. Review.

41.

Mechanisms of IVIG efficacy in chronic inflammatory demyelinating polyneuropathy.

Tackenberg B, Nimmerjahn F, Lünemann JD.

J Clin Immunol. 2010 May;30 Suppl 1:S65-9. doi: 10.1007/s10875-010-9398-1. Review.

PMID:
20424898
42.

B cell expression of the inhibitory Fc gamma receptor is unchanged in early MS.

Comabella M, Montalban X, Kakalacheva K, Osman D, Nimmerjahn F, Tintoré M, Lünemann JD.

J Neuroimmunol. 2010 Jun;223(1-2):135-7. doi: 10.1016/j.jneuroim.2010.03.015.

PMID:
20399509
43.

Elevated Epstein-Barr virus-encoded nuclear antigen-1 immune responses predict conversion to multiple sclerosis.

Lünemann JD, Tintoré M, Messmer B, Strowig T, Rovira A, Perkal H, Caballero E, Münz C, Montalban X, Comabella M.

Ann Neurol. 2010 Feb;67(2):159-69. doi: 10.1002/ana.21886.

44.

Antiviral immune response in patients with multiple sclerosis and healthy siblings.

Comabella M, Montalban X, Horga A, Messmer B, Kakalacheva K, Strowig T, Caballero E, Münz C, Lünemann J.

Mult Scler. 2010 Mar;16(3):355-8. doi: 10.1177/1352458509357066.

PMID:
20203149
45.

Autophagy-mediated antigen processing in CD4(+) T cell tolerance and immunity.

Klein L, Münz C, Lünemann JD.

FEBS Lett. 2010 Apr 2;584(7):1405-10. doi: 10.1016/j.febslet.2010.01.008. Epub 2010 Jan 12. Review.

46.

Dysregulated Epstein-Barr virus infection in patients with CIDP.

Lünemann JD, Tackenberg B, Stein A, Wandinger KP, Oertel WH, Wagner HJ, Münz C, Meisel H, Sommer N, Zipp F.

J Neuroimmunol. 2010 Jan 25;218(1-2):107-11. doi: 10.1016/j.jneuroim.2009.11.003. Epub 2009 Nov 24.

PMID:
19939466
47.

A type I interferon signature in monocytes is associated with poor response to interferon-beta in multiple sclerosis.

Comabella M, Lünemann JD, Río J, Sánchez A, López C, Julià E, Fernández M, Nonell L, Camiña-Tato M, Deisenhammer F, Caballero E, Tortola MT, Prinz M, Montalban X, Martin R.

Brain. 2009 Dec;132(Pt 12):3353-65. doi: 10.1093/brain/awp228.

PMID:
19741051
48.

Regulatory NK-cell functions in inflammation and autoimmunity.

Lünemann A, Lünemann JD, Münz C.

Mol Med. 2009 Sep-Oct;15(9-10):352-8. doi: 10.2119/molmed.2009.00035. Epub 2009 May 11. Review.

49.

Immune responses to EBNA1: biomarkers in MS?

Lünemann JD, Ascherio A.

Neurology. 2009 Jul 7;73(1):13-4. doi: 10.1212/WNL.0b013e3181aa2a5f. Epub 2009 May 20. No abstract available.

PMID:
19458320
50.

EBV in MS: guilty by association?

Lünemann JD, Münz C.

Trends Immunol. 2009 Jun;30(6):243-8. doi: 10.1016/j.it.2009.03.007. Epub 2009 May 8.

PMID:
19428300

Supplemental Content

Loading ...
Support Center